Algernon Pharmaceuticals (Algernon Pharmaceuticals) ROE % Adjusted to Book Value : -122.26% (As of Nov. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Algernon Pharmaceuticals ROE % Adjusted to Book Value?

Algernon Pharmaceuticals's ROE % for the quarter that ended in Nov. 2023 was -166.28%. Algernon Pharmaceuticals's PB Ratio for the quarter that ended in Nov. 2023 was 1.36. Algernon Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Nov. 2023 was -122.26%.

Algernon Pharmaceuticals ROE % Adjusted to Book Value Historical Data

The historical data trend for Algernon Pharmaceuticals's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Algernon Pharmaceuticals ROE % Adjusted to Book Value Chart

Algernon Pharmaceuticals Annual Data

Trend

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-52.25

-26.17

-41.65

-36.43

-106.13

Algernon Pharmaceuticals Quarterly Data
	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-111.50	-110.08	-153.90	-223.97	-122.26

Competitive Comparison of Algernon Pharmaceuticals's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Algernon Pharmaceuticals's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Algernon Pharmaceuticals's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Algernon Pharmaceuticals's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Algernon Pharmaceuticals's ROE % Adjusted to Book Value falls into.

Algernon Pharmaceuticals ROE % Adjusted to Book Value Calculation

Algernon Pharmaceuticals's ROE % Adjusted to Book Value for the fiscal year that ended in Aug. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-184.66%	/	1.74
	=	-106.13%

Algernon Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Nov. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-166.28%	/	1.36
	=	-122.26%

Algernon Pharmaceuticals ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Algernon Pharmaceuticals's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Algernon Pharmaceuticals (Algernon Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Algernon Pharmaceuticals Inc (OTCPK:AGNPF) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

AGW0:Germany AGN:Canada

Address

601 West Broadway, Suite 400, Vancouver, BC, CAN, V5Z 4C2

Website

https://www.algernonpharmaceuticals.com

Algernon Pharmaceuticals Inc is a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis and chronic cough. The company's business model is capital efficient and strives to deliver maximum shareholder value. Algernon's approach to drug discovery is based on the concept of drug repurposing. It operates in two reportable segments: the development of repurposed therapeutic drugs in Canada, and the facilitation of the Company's drug candidates into off-label phase II clinical trials (humans) in Australia.